Ls Investment Advisors, LLC Nektar Therapeutics Transaction History

Ls Investment Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $166,196 - $255,516	-10,036 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$16.86 - $23.44 $6,794 - $9,446	403 Added 4.18%	10,036 $232,000
Q4 2019 Jan 31, 2020	SELL	$15.87 - $23.12 $40,992 - $59,718	-2,583 Reduced 21.14%	9,633 $208,000
Q3 2019 Oct 31, 2019	BUY	$16.91 - $36.27 $66,371 - $142,359	3,925 Added 47.34%	12,216 $223,000
Q1 2019 Apr 25, 2019	BUY	$31.58 - $46.35 $7,137 - $10,475	226 Added 2.8%	8,291 $279,000
Q4 2018 Feb 01, 2019	BUY	$30.43 - $56.65 $5,994 - $11,160	197 Added 2.5%	8,065 $265,000
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $9,710 - $14,314	-209 Reduced 2.59%	7,868 $480,000
Q2 2018 Jul 20, 2018	BUY	$46.25 - $104.45 $122,053 - $275,643	2,639 Added 48.53%	8,077 $394,000
Q1 2018 May 08, 2018	SELL	$57.4 - $108.44 $40,754 - $76,992	-710 Reduced 11.55%	5,438 $578,000
Q4 2017 Feb 07, 2018	BUY	$23.02 - $60.5 $9,829 - $25,833	427 Added 7.46%	6,148 $367,000
Q3 2017 Oct 19, 2017	BUY	$17.79 - $24.0 $101,776 - $137,304	5,721	5,721 $137,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $127M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Ls Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ls Investment Advisors, LLC with notifications on news.